Becton Dickinson Research and Development Expenses 2012-2026 | BDX
Becton Dickinson annual/quarterly research and development expenses history and growth rate from 2012 to 2026. Research and development expenses can be defined as an expense arising from studies and product development processes.
- Becton Dickinson research and development expenses for the quarter ending March 31, 2026 were $249M, a 17.55% decline year-over-year.
- Becton Dickinson research and development expenses for the twelve months ending March 31, 2026 were $1.175B, a 5.7% decline year-over-year.
- Becton Dickinson annual research and development expenses for 2025 were $1.265B, a 6.3% increase from 2024.
- Becton Dickinson annual research and development expenses for 2024 were $1.19B, a 3.8% decline from 2023.
- Becton Dickinson annual research and development expenses for 2023 were $1.237B, a 1.51% decline from 2022.
|
Becton Dickinson Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2025 | $1,265 |
| 2024 | $1,190 |
| 2023 | $1,237 |
| 2022 | $1,256 |
| 2021 | $1,279 |
| 2020 | $1,039 |
| 2019 | $1,062 |
| 2018 | $1,004 |
| 2017 | $770 |
| 2016 | $828 |
| 2015 | $632 |
| 2014 | $550 |
| 2013 | $494 |
| 2012 | $472 |
| 2011 | $470 |
|
Becton Dickinson Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2026-03-31 | $249 |
| 2025-12-31 | $306 |
| 2025-09-30 | $323 |
| 2025-06-30 | $297 |
| 2025-03-31 | $302 |
| 2024-12-31 | $343 |
| 2024-09-30 | $302 |
| 2024-06-30 | $299 |
| 2024-03-31 | $299 |
| 2023-12-31 | $290 |
| 2023-09-30 | $281 |
| 2023-06-30 | $306 |
| 2023-03-31 | $337 |
| 2022-12-31 | $313 |
| 2022-09-30 | $300 |
| 2022-06-30 | $315 |
| 2022-03-31 | $327 |
| 2021-12-31 | $314 |
| 2021-09-30 | $341 |
| 2021-06-30 | $330 |
| 2021-03-31 | $317 |
| 2020-12-31 | $291 |
| 2020-09-30 | $243 |
| 2020-06-30 | $262 |
| 2020-03-31 | $264 |
| 2019-12-31 | $270 |
| 2019-09-30 | $270 |
| 2019-06-30 | $282 |
| 2019-03-31 | $252 |
| 2018-12-31 | $258 |
| 2018-09-30 | $277 |
| 2018-06-30 | $277 |
| 2018-03-31 | $259 |
| 2017-12-31 | $191 |
| 2017-09-30 | $215 |
| 2017-06-30 | $186 |
| 2017-03-31 | $187 |
| 2016-12-31 | $182 |
| 2016-09-30 | $252 |
| 2016-06-30 | $207 |
| 2016-03-31 | $182 |
| 2015-12-31 | $187 |
| 2015-09-30 | $196 |
| 2015-06-30 | $178 |
| 2015-03-31 | $129 |
| 2014-12-31 | $129 |
| 2014-09-30 | $140 |
| 2014-06-30 | $137 |
| 2014-03-31 | $147 |
| 2013-12-31 | $126 |
| 2013-09-30 | $133 |
| 2013-06-30 | $121 |
| 2013-03-31 | $122 |
| 2012-12-31 | $118 |
| 2012-09-30 | $128 |
| 2012-06-30 | $115 |
| 2012-03-31 | $117 |
| 2011-12-31 | $112 |
| 2011-09-30 | $121 |
| 2011-06-30 | $114 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical & Dental Supplies | $43.913B | $21.840B |
| Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| McKesson (MCK) | United States | $106.025B | 23.03 |
| Cardinal Health (CAH) | United States | $50.715B | 22.43 |
| West Pharmaceutical Services (WST) | United States | $18.493B | 35.19 |
| Straumann Holding AG (SAUHY) | Switzerland | $16.902B | 0.00 |
| Cooper (COO) | United States | $13.894B | 16.52 |
| Align Technology (ALGN) | United States | $12.400B | 21.09 |
| Henry Schein (HSIC) | United States | $8.645B | 15.16 |
| Merit Medical Systems (MMSI) | United States | $4.072B | 19.84 |
| DENTSPLY SIRONA (XRAY) | United States | $2.339B | 7.36 |
| STAAR Surgical (STAA) | United States | $1.309B | 0.00 |
| CONMED (CNMD) | United States | $1.107B | 7.97 |
| Pro-Dex (PDEX) | United States | $0.165B | 19.65 |
| Lifevantage (LFVN) | United States | $0.053B | 5.46 |
| Axe Compute (AGPU) | United States | $0.022B | 0.00 |